查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1776724

数位治疗 (DTx) 市场预测至 2032 年：按产品、收益模式、销售管道、部署模式、应用、最终用户和地区进行的全球分析

Digital Therapeutics (DTx) Market Forecasts to 2032 - Global Analysis By Product (Software & Services and Devices), Revenue Modal, Sales Channel, Deployment Mode, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球数位治疗 (DTx) 市场预计在 2025 年达到 103 亿美元，到 2032 年将达到 499 亿美元，预测期内的复合年增长率为 25.2%。

Digital Therapeutics (DTx) 是经临床评估的实证软体程序，旨在治疗、管理或预防各种疾病。 Digital Therapeutics 使用智慧型手机和平板电脑等设备直接向患者提供治疗性介入，通常作为传统疗法的补充。与一般健康应用程式不同，DTx 经过严格的临床试验和监管审查，以确保安全性和有效性。 DTx 可以治疗各种疾病，从糖尿病、失眠到焦虑和过动症。透过结合个人化回馈、数据追踪和行为科学，DTx 帮助个人掌控自身健康并改善临床疗效。

根据世界卫生组织（WHO）的数据，2019年，超过10亿高血压患者（占全球高血压患者的82%）生活在中低收入国家。

慢性病盛行率上升

糖尿病、心血管疾病和呼吸系统疾病等慢性疾病的盛行率不断上升，是数位治疗 (DTx) 市场的主要驱动力。随着这些长期疾病对全球带来的负担日益加重，对可扩展、个人化且经济高效的照护解决方案的需求也日益增长。 DTx 平台提供持续监测、行为矫正和提升病人参与，进而改善治疗效果。主动和远距疾病管理的转变正在推动整个医疗保健系统的采用，使 DTx 成为现代慢性病照护模式的重要组成部分。

资料隐私和网路安全问题

对资料隐私和网路安全的担忧正在阻碍数位治疗 (DTx) 市场的成长。由于 DTx 平台处理敏感的医疗讯息，其易受资料外洩和未授权存取的影响，引发了严重的信任和合规性问题。这些风险阻碍了患者的采用，并减缓了医疗服务提供者的整合。 HIPAA 和 GDPR 等日益严格的法规也增加了开发的复杂性和成本，使得安全和可扩展的部署成为全球 DTx 公司持续面临的挑战。

向预防性医疗保健的转变

全球向预防性医疗保健的转变正在推动数位治疗 (DTx) 市场的强劲成长。由于医疗保健系统优先考虑早期疗育和健康而非被动治疗，DTx 解决方案提供个人化的生活方式管理、风险降低和长期疾病预防方案。这些工具使患者能够透过即时回馈、行为指导和数位互动来掌控自己的健康。这种模式转移正在推动对 DTx 平台的需求，使其成为全球现代、经济高效的预防性医疗保健策略的重要组成部分。

开发和维护成本高

高昂的开发和维护成本是数位治疗 (DTx) 市场成长的主要障碍。创建经临床检验且符合法规要求的 DTx 解决方案需要在研究、设计和持续更新方面投入大量资金。中小企业通常面临资源限制，限制了创新和市场准入。此外，持续的技术支援和平台安全需求也增加了营运成本，使得在成本敏感的医疗保健环境中难以实现扩充性和普及性。

COVID-19的影响

新冠疫情加速了数位疗法 (DTx) 的普及，因为封锁和保持社交距离凸显了远距医疗解决方案的需求。由于面对面就诊受限，患者和医疗服务提供者纷纷转向数位平台进行慢性病管理、心理健康支援和预防保健。远端医疗的普及激增，提升了 DTx 的认知和整合度，巩固了其作为后疫情时代医疗生态系统中具有韧性和可扩展性的解决方案的地位。

戒烟市场预计将成为预测期内最大的市场

由于人们日益意识到吸烟带来的健康风险，预计戒烟领域将在预测期内占据最大的市场占有率。 DTx平台提供基于证据的可扩展干预措施，包括认知行为疗法、数位辅导和个人化追踪，以帮助个人有效戒烟。这些技术驱动的方法提供了便捷的非侵入性支持，可提高戒烟成功率和长期戒烟效果。随着社会和临床对戒烟工具的需求不断增长，DTx解决方案正逐渐成为行为健康管理的重要组成部分。

糖尿病领域预计在预测期内实现最高复合年增长率

由于全球第1型和第2型糖尿病的盛行率不断上升，预计糖尿病领域将在预测期内达到最高成长率。 DTx解决方案提供有效的自我管理工具，包括血糖监测、饮食建议和数位指导，帮助患者更好地控制病情。这种个人化、数据主导的介入措施可以提高患者服药顺从性，并改善临床疗效。随着医疗保健系统寻求经济高效的慢性病治疗方案，对数位化糖尿病管理的需求正在稳步推动DTx市场的扩张。

比最大的地区

在预测期内，亚太地区预计将占据最大的市场占有率，这得益于快速的数位转型、慢性病盛行率的上升以及智慧型手机普及率的提高。各国政府和医疗机构正在采用 DTx，以增强偏远地区的医疗服务，并减轻系统负担。印度、中国和日本等国家凭藉其精通技术的人口和不断扩张的医疗基础设施，在 DTx 应用方面处于领先地位。这种有利的环境正在推动创新和投资，使亚太地区成为下一代以患者为中心的数位医疗解决方案的活力中心。

复合年增长率最高的地区：

由于先进的医疗基础设施、较高的数位素养以及有利的监管支持，北美地区预计将在预测期内实现最高的复合年增长率。该地区正在积极采用技术赋能的医疗保健，尤其是在慢性病管理领域，这使得远距医疗 (DTx) 成为现代医学的基石。策略性投资、不断扩大的保险覆盖范围以及强有力的临床检验进一步推动了市场发展势头。随着个人化远距照护解决方案需求的不断增长，北美地区将继续在各个治疗领域的远距医疗创新与整合方面引领产业发展。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球数位治疗 (DTx) 市场（按产品）

  • 软体和服务
  • 装置

6. 全球数位治疗 (DTx) 市场按收益模式划分

  • 订阅
  • 一次性购买/许可
  • 基于结果/价值

7. 全球数位治疗 (DTx) 市场按销售管道

  • 企业对企业（B2B）
  • 企业对消费者（B2C）

8. 全球数位治疗 (DTx) 市场（按部署模式）

  • 本地
  • 云端基础

9. 全球数位治疗 (DTx) 市场（按应用）

  • 糖尿病
  • 肥胖
  • 心血管疾病
  • 呼吸系统疾病
  • 中枢神经系统 (CNS) 疾病
  • 禁止抽烟
  • 胃肠道疾病
  • 其他用途

第 10 章：全球数位治疗 (DTx) 市场（按最终用户划分）

  • 病人
  • 提供者
  • 付款人
  • 雇主
  • 其他最终用户

第 11 章：全球数位治疗 (DTx) 市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Pear Therapeutics, Inc.
  • Omada Health, Inc.
  • Livongo Health, Inc.
  • Propeller Health
  • Akili Interactive Labs, Inc.
  • Better Therapeutics, Inc.
  • Voluntis, Inc.
  • Kaia Health
  • Happify Health
  • WellDoc, Inc.
  • Cognoa, Inc.
  • Click Therapeutics, Inc.
  • Big Health
  • Canary Health
  • Biofourmis
  • Lark Health
  • 2Morrow, Inc.
  • DarioHealth Corp.
  • MindMaze
  • SilverCloud Health
Product Code: SMRC30055

According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $10.3 billion in 2025 and is expected to reach $49.9 billion by 2032 growing at a CAGR of 25.2% during the forecast period. Digital Therapeutics (DTx) is evidence-based, clinically evaluated software programs designed to treat, manage, or prevent medical disorders and diseases. They deliver therapeutic interventions directly to patients using devices like smartphones or tablets, often supplementing traditional treatments. Unlike general wellness apps, DTx undergo rigorous clinical trials and regulatory review to ensure safety and efficacy. They can address a wide range of conditions, from diabetes and insomnia to anxiety and ADHD. By combining personalized feedback, data tracking, and behavioral science, DTx empower individuals to take control of their health and improve clinical outcomes-all without relying solely on medication or in-person care.

According to World Health Organization (WHO), in 2019, over one billion people with hypertension (82% of all people with hypertension worldwide) lived in low and middle-income countries.

Market Dynamics:

Driver:

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions is significantly propelling the Digital Therapeutics (DTx) market. As the global burden of these long-term conditions increases, there is growing demand for scalable, personalized, and cost-effective care solutions. DTx platforms offer continuous monitoring, behavior modification, and improved patient engagement, enhancing treatment outcomes. This shift toward proactive and remote disease management is driving adoption across healthcare systems, making DTx an essential component in modern chronic care models.

Restraint:

Data Privacy & Cybersecurity Concerns

Concerns over data privacy and cybersecurity are hampering the growth of the Digital Therapeutics (DTx) market. As DTx platforms handle sensitive health information, vulnerabilities to data breaches and unauthorized access raise serious trust and compliance issues. These risks deter patient adoption and slow provider integration. Stricter regulations like HIPAA and GDPR also increase the complexity and cost of development, making secure, scalable deployment a persistent challenge for DTx companies worldwide.

Opportunity:

Shift toward Preventive Healthcare

The global shift toward preventive healthcare is fueling robust growth in the Digital Therapeutics (DTx) market. As healthcare systems prioritize early intervention and wellness over reactive treatment, DTx solutions offer personalized programs for lifestyle management, risk reduction, and long-term disease prevention. These tools empower patients to take control of their health through real-time feedback, behavior coaching, and digital engagement. This paradigm shift is increasing demand for DTx platforms, positioning them as integral to modern, and cost-effective preventive care strategies worldwide.

Threat:

High Development & Maintenance Costs

High development and maintenance costs pose a significant barrier to the growth of the Digital Therapeutics (DTx) market. Creating clinically validated, regulatory-compliant DTx solutions requires substantial investment in research, design, and ongoing updates. Smaller companies often struggle with resource constraints, limiting innovation and market entry. Additionally, the need for continuous technical support and platform security increases operational expenses, making scalability and widespread adoption more challenging in cost-sensitive healthcare environments.

Covid-19 Impact

The COVID-19 pandemic accelerated the adoption of Digital Therapeutics (DTx) as lockdowns and social distancing highlighted the need for remote healthcare solutions. With in-person visits limited, patients and providers turned to digital platforms for chronic disease management, mental health support, and preventive care. This surge in telehealth acceptance boosted awareness and integration of DTx, solidifying its role as a resilient, scalable solution in post-pandemic healthcare ecosystems.

The smoking cessation segment is expected to be the largest during the forecast period

The smoking cessation segment is expected to account for the largest market share during the forecast period, due to rising awareness of smoking-related health risks. DTx platforms offer evidence-based, scalable interventions-like cognitive behavioral therapy, digital coaching, and personalized tracking-to help individuals quit smoking effectively. These tech-enabled approaches provide accessible, non-invasive support that enhances success rates and long-term abstinence. As public and clinical demand for smoking cessation tools grows, DTx solutions are gaining prominence as vital components in behavioral health management.

The diabetes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diabetes segment is predicted to witness the highest growth rate, due to increasing global prevalence of Type 1 and Type 2 diabetes. DTx solutions offer effective self-management tools, including glucose monitoring, dietary guidance, and digital coaching, empowering patients to better control their condition. These personalized, data-driven interventions enhance adherence and improve clinical outcomes. As healthcare systems seek cost-efficient chronic care solutions, the demand for digital diabetes management is steadily fueling expansion across the DTx landscape.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rapid digital transformation, rising chronic disease prevalence, and increasing smartphone penetration. Governments and healthcare providers are embracing DTx to enhance remote care access and reduce system burdens. With tech-savvy populations and expanding healthcare infrastructure, countries like India, China, and Japan are leading adoption. This favorable environment is driving innovation and investment, positioning Asia Pacific as a dynamic hub for next-generation, patient-centered digital healthcare solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure, high digital literacy, and favorable regulatory support. The region's proactive adoption of tech-enabled healthcare, especially in managing chronic conditions, positions DTx as a cornerstone of modern medical care. Strategic investments, insurance coverage expansion, and strong clinical validation further boost market momentum. With increasing demand for personalized and remote care solutions, North America continues to lead innovation and integration of DTx across diverse therapeutic areas.

Key players in the market

Some of the key players profiled in the Digital Therapeutics (DTx) Market include Pear Therapeutics, Inc., Omada Health, Inc., Livongo Health, Inc., Propeller Health, Akili Interactive Labs, Inc., Better Therapeutics, Inc., Voluntis, Inc., Kaia Health, Happify Health, WellDoc, Inc., Cognoa, Inc., Click Therapeutics, Inc., Big Health, Canary Health, Biofourmis, Lark Health, 2Morrow, Inc., DarioHealth Corp., MindMaze and SilverCloud Health.

Key Developments:

In June 2022, Happify Health, in collaboration with Almirall, launched Claro, a digital wellness program for individuals living with psoriasis in the UK, Spain, and Italy. Designed to tackle the common mental health challenges associated with the condition affecting 20-30% of moderate-to-severe patients-Claro integrates cognitive behavioral therapy, positive psychology, and mindfulness to boost emotional resilience and quality of life.

In August 2021, Happify Health and Higi have joined forces to deliver AI-powered, digitally personalized healthcare through Higi's expansive network of over 10,000 Smart Health Stations located in US retail outlets, including pharmacies and grocery stores.

Products Covered:

  • Software & Services
  • Devices

Revenue Modals Covered:

  • Subscription
  • One time Purchase/Licensing
  • Outcome/Value based

Sales Channels Covered:

  • Business-to-Business (B2B)
  • Business-to-Consumer (B2C)

Deployment Modes Covered:

  • On-Premises
  • Cloud-Based

Applications Covered:

  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Central Nervous System (CNS) Disorders
  • Smoking Cessation
  • Gastrointestinal Disorders
  • Other Applications

End Users Covered:

  • Patients
  • Providers
  • Payers
  • Employers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics (DTx) Market, By Product

  • 5.1 Introduction
  • 5.2 Software & Services
  • 5.3 Devices

6 Global Digital Therapeutics (DTx) Market, By Revenue Modal

  • 6.1 Introduction
  • 6.2 Subscription
  • 6.3 One time Purchase/Licensing
  • 6.4 Outcome/Value based

7 Global Digital Therapeutics (DTx) Market, By Sales Channel

  • 7.1 Introduction
  • 7.2 Business-to-Business (B2B)
  • 7.3 Business-to-Consumer (B2C)

8 Global Digital Therapeutics (DTx) Market, By Deployment Mode

  • 8.1 Introduction
  • 8.2 On-Premises
  • 8.3 Cloud-Based

9 Global Digital Therapeutics (DTx) Market, By Application

  • 9.1 Introduction
  • 9.2 Diabetes
  • 9.3 Obesity
  • 9.4 Cardiovascular Diseases
  • 9.5 Respiratory Diseases
  • 9.6 Central Nervous System (CNS) Disorders
  • 9.7 Smoking Cessation
  • 9.8 Gastrointestinal Disorders
  • 9.9 Other Applications

10 Global Digital Therapeutics (DTx) Market, By End User

  • 10.1 Introduction
  • 10.2 Patients
  • 10.3 Providers
  • 10.4 Payers
  • 10.5 Employers
  • 10.6 Other End Users

11 Global Digital Therapeutics (DTx) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pear Therapeutics, Inc.
  • 13.2 Omada Health, Inc.
  • 13.3 Livongo Health, Inc.
  • 13.4 Propeller Health
  • 13.5 Akili Interactive Labs, Inc.
  • 13.6 Better Therapeutics, Inc.
  • 13.7 Voluntis, Inc.
  • 13.8 Kaia Health
  • 13.9 Happify Health
  • 13.10 WellDoc, Inc.
  • 13.11 Cognoa, Inc.
  • 13.12 Click Therapeutics, Inc.
  • 13.13 Big Health
  • 13.14 Canary Health
  • 13.15 Biofourmis
  • 13.16 Lark Health
  • 13.17 2Morrow, Inc.
  • 13.18 DarioHealth Corp.
  • 13.19 MindMaze
  • 13.20 SilverCloud Health

List of Tables

  • Table 1 Global Digital Therapeutics (DTx) Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics (DTx) Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics (DTx) Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics (DTx) Market Outlook, By Devices (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics (DTx) Market Outlook, By Revenue Modal (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics (DTx) Market Outlook, By Subscription (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics (DTx) Market Outlook, By One time Purchase/Licensing (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics (DTx) Market Outlook, By Outcome/Value based (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics (DTx) Market Outlook, By Sales Channel (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Business (B2B) (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Consumer (B2C) (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics (DTx) Market Outlook, By Deployment Mode (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics (DTx) Market Outlook, By On-Premises (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics (DTx) Market Outlook, By Cloud-Based (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics (DTx) Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics (DTx) Market Outlook, By Diabetes (2024-2032) ($MN)
  • Table 17 Global Digital Therapeutics (DTx) Market Outlook, By Obesity (2024-2032) ($MN)
  • Table 18 Global Digital Therapeutics (DTx) Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 19 Global Digital Therapeutics (DTx) Market Outlook, By Respiratory Diseases (2024-2032) ($MN)
  • Table 20 Global Digital Therapeutics (DTx) Market Outlook, By Central Nervous System (CNS) Disorders (2024-2032) ($MN)
  • Table 21 Global Digital Therapeutics (DTx) Market Outlook, By Smoking Cessation (2024-2032) ($MN)
  • Table 22 Global Digital Therapeutics (DTx) Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 23 Global Digital Therapeutics (DTx) Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 24 Global Digital Therapeutics (DTx) Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Digital Therapeutics (DTx) Market Outlook, By Patients (2024-2032) ($MN)
  • Table 26 Global Digital Therapeutics (DTx) Market Outlook, By Providers (2024-2032) ($MN)
  • Table 27 Global Digital Therapeutics (DTx) Market Outlook, By Payers (2024-2032) ($MN)
  • Table 28 Global Digital Therapeutics (DTx) Market Outlook, By Employers (2024-2032) ($MN)
  • Table 29 Global Digital Therapeutics (DTx) Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.